220 related articles for article (PubMed ID: 37788669)
1. Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement.
Gray ZH; Chakraborty D; Duttweiler RR; Alekbaeva GD; Murphy SE; Chetal K; Ji F; Ferman BI; Honer MA; Wang Z; Myers C; Sun R; Kaniskan HÜ; Toma MM; Bondarenko EA; Santoro JN; Miranda C; Dillingham ME; Tang R; Gozani O; Jin J; Skorski T; Duy C; Lee H; Sadreyev RI; Whetstine JR
Cell; 2023 Oct; 186(21):4528-4545.e18. PubMed ID: 37788669
[TBL] [Abstract][Full Text] [Related]
2. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
3. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
4. KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm.
Yang N; Huh J; Chung WS; Cho MS; Ryu KH; Chung HS
Cancer Genet; 2015 Sep; 208(9):464-7. PubMed ID: 26164398
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
6. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
Peterson JF; Baughn LB; Pearce KE; Williamson CM; Benevides Demasi JC; Olson RM; Goble TA; Meyer RG; Greipp PT; Ketterling RP
Genes Chromosomes Cancer; 2018 Nov; 57(11):541-546. PubMed ID: 30203571
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
Zerkalenkova E; Lebedeva S; Kazakova A; Tsaur G; Starichkova Y; Timofeeva N; Soldatkina O; Aprelova E; Popov A; Ponomareva N; Baidun L; Meyer C; Novichkova G; Maschan M; Maschan A; Marschalek R; Olshanskaya Y
Int J Lab Hematol; 2019 Apr; 41(2):287-292. PubMed ID: 30624859
[TBL] [Abstract][Full Text] [Related]
8. MLL/KMT2A translocations in diffuse large B-cell lymphomas.
Gindin T; Murty V; Alobeid B; Bhagat G
Hematol Oncol; 2015 Dec; 33(4):239-46. PubMed ID: 25131304
[TBL] [Abstract][Full Text] [Related]
9. Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical Characteristics With KMT2A (MLL) Gene Rearrangement Correlation.
El Jamal SM; Salama A; Marcellino BK; Abulsayen HA; Zhou X; Hassan M; Firpo-Betancourt A; Saad AG
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):501-507. PubMed ID: 31241561
[TBL] [Abstract][Full Text] [Related]
10. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
Blackburn PR; Smadbeck JB; Znoyko I; Webley MR; Pitel BA; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Lindsey KG; Schandl CA; Wolff DJ; Peterson JF
Genes Chromosomes Cancer; 2020 Jul; 59(7):422-427. PubMed ID: 32196814
[TBL] [Abstract][Full Text] [Related]
11. A new variant of KMT2A(MLL)-FLNA fusion transcript in acute myeloid leukemia with ins(X;11)(q28;q23q23).
Matveeva E; Kazakova A; Olshanskaya Y; Tsaur G; Shelikhova L; Meyer C; Marschalek R; Novichkova G; Maschan M; Maschan A
Cancer Genet; 2015 Apr; 208(4):148-51. PubMed ID: 25892123
[TBL] [Abstract][Full Text] [Related]
12. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
[TBL] [Abstract][Full Text] [Related]
14. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential.
Wong SH; Goode DL; Iwasaki M; Wei MC; Kuo HP; Zhu L; Schneidawind D; Duque-Afonso J; Weng Z; Cleary ML
Cancer Cell; 2015 Aug; 28(2):198-209. PubMed ID: 26190263
[TBL] [Abstract][Full Text] [Related]
15. KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
Xu X; Nagel S; Quentmeier H; Wang Z; Pommerenke C; Dirks WG; Macleod RAF; Drexler HG; Hu Z
Leuk Lymphoma; 2018 Jan; 59(1):204-213. PubMed ID: 28540746
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
Nanya M; Sato M; Tanimoto K; Tozuka M; Mizutani S; Takagi M
PLoS One; 2015; 10(12):e0144540. PubMed ID: 26657054
[TBL] [Abstract][Full Text] [Related]
18. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
19. The MLL recombinome of acute leukemias in 2017.
Meyer C; Burmeister T; Gröger D; Tsaur G; Fechina L; Renneville A; Sutton R; Venn NC; Emerenciano M; Pombo-de-Oliveira MS; Barbieri Blunck C; Almeida Lopes B; Zuna J; Trka J; Ballerini P; Lapillonne H; De Braekeleer M; Cazzaniga G; Corral Abascal L; van der Velden VHJ; Delabesse E; Park TS; Oh SH; Silva MLM; Lund-Aho T; Juvonen V; Moore AS; Heidenreich O; Vormoor J; Zerkalenkova E; Olshanskaya Y; Bueno C; Menendez P; Teigler-Schlegel A; Zur Stadt U; Lentes J; Göhring G; Kustanovich A; Aleinikova O; Schäfer BW; Kubetzko S; Madsen HO; Gruhn B; Duarte X; Gameiro P; Lippert E; Bidet A; Cayuela JM; Clappier E; Alonso CN; Zwaan CM; van den Heuvel-Eibrink MM; Izraeli S; Trakhtenbrot L; Archer P; Hancock J; Möricke A; Alten J; Schrappe M; Stanulla M; Strehl S; Attarbaschi A; Dworzak M; Haas OA; Panzer-Grümayer R; Sedék L; Szczepański T; Caye A; Suarez L; Cavé H; Marschalek R
Leukemia; 2018 Feb; 32(2):273-284. PubMed ID: 28701730
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic strategies for MLL-rearranged leukemias.
Wong NM; So CWE
Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
